JAZZ - Jazz Pharmaceuticals plc News

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $296

RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperfor

Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy a

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Financial Comparison: Jazz Pharmaceuticals (NASDAQ:JAZZ) vs. vTv Therapeutics (NASDAQ:VTVT)

Jazz Pharmaceuticals (NASDAQ: JAZZ - Get Free Report) and vTv Therapeutics (NASDAQ: VTVT - Get Free

Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and

Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds fo

Iambic Therapeutics, an AI drug discovery company backed by Nvidia and the Qatar Investment Authorit

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals (NASDAQ: JAZZ) outlined development and commercial plans for its oncology, epil

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals (NASDAQ: JAZZ) executives outlined the company's oncology growth strategy, earl

marketbeat.com

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company's oncology growth strategy, early

marketbeat.com

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilep

fool.com

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

Jazz paid $820 million up front to acquire Actio Biosciences. Actio shareholders could receive anoth

Engineers Gate Manager LP Reduces Stock Position in Jazz Pharmaceuticals PLC $JAZZ

Engineers Gate Manager LP cut its holdings in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 93.2% durin

Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-re

UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

UBS analyst Ashwani Verma maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the

Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcr

AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study

Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, poten

Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that c

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

JAZZ Rises on Updated OS Results From Gastric Cancer Study

Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-bas

Jazz Reports Ziihera Outperformed Standard Treatment In Late-Stage Cancer Trial

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced second interim top-line overall survival (OS)

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Surviva

HERIZON-GEA-01 results reinforce recently FDA-approved Ziihera as the definitive HER2-targeted backb

Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA

Jazz Pharmaceuticals (NASDAQ: JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA

Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchang

DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals

Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and rai

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweigh

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal

Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $281

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy a

MongoDB To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT

Jazz Pharmaceuticals Announces Private Offering Of $1B Of Exchangeable Senior Notes Due 2032; Expec

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz In

Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $310

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the com

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positiv

Jazz Pharmaceuticals' Two Ziihera-Containing Regimens Receives FDA Approval To Treat Adults With Unr

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (F

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $283

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweigh

Jazz Pharmaceuticals To Acquire Developer Of Epilepsy Therapy Biotech Actio Biosciences For $820M Up

Actio Biosciences' lead clinical asset is ABS-1230, a novel, first-in-class small molecule preci

JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $276

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $264

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy a

TD Cowen Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

TD Cowen analyst Joseph Thome maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises

Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300

Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight a

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $280

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweigh

Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweig

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. A

Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $292

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the

Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $270

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Baird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $280

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and rais